Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
You must be a Standard 1 Year member to access this content.
Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Protagonist Therapeutics, Inc. on its worldwide license and collaboration agreement with Takeda. PJT Partners acted as the exclusive financial advisor...
You must be a Standard 1 Year member to access this content.
